New hope for liver cancer patients with liver damage: drug tested after immunotherapy fails
NCT ID NCT07514455
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests the cancer pill regorafenib in 20 adults with advanced liver cancer and moderate liver dysfunction (Child-Pugh B) whose disease worsened after first-line immunotherapy. Participants take regorafenib daily for 3 weeks on, 1 week off, until the cancer progresses or side effects become too severe. The main goal is to see if the drug delays cancer growth better than no treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- regorafenib (a targeted cancer drug taken as a pill)
- What this could lead to
- If successful, this could provide a second-line treatment option for liver cancer patients with moderate liver impairment who have no approved therapies after immunotherapy fails.
- What could go wrong
- This is a very small, early-phase trial with only 20 participants. The drug may not improve survival or could cause significant side effects, especially in patients with already compromised liver function.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, HEPATOCELLULAR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Asan Medical Center
Seoul, 05505, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple belly press make liver cancer radiation more precise?
- A new way to read CT scans may predict which liver surgery patients will develop Life-Threatening failure
- Home hospital care for infections: when does it fail?
- Virus hunts liver tumors before chemo strikes
- Can immune and imaging clues predict heart valve disease progression?
- New combo therapy aims to stop liver cancer from coming back